Medical Devices

Public Workshop - Clinical Flow Cytometry in Hematologic Malignancies, February 25-26, 2013

The purpose of this public workshop is to seek input from academia, Government, laboratorians, industry, clinicians, patients and other stakeholders on the role of clinical flow cytometry in hematologic malignancies, in order to develop a specific regulatory policy for this class of in vitro diagnostic devices.

Date, Time and Location

This meeting was held February 25 and 26, 2013, beginning at 8:00 a.m. at the following location:

FDA White Oak Campus
10903 New Hampshire Avenue,
Building 31, Conference Center (Great Room 1503)
Silver Spring, MD 20993

Back to Top Arrow


February 25

February 26

Back to Top Arrow


Back to Top Arrow


Topics for discussion during this workshop include:

  1. Overview of Quality control and standardization issues associated with Clinical Flow Cytometry (FCM), including discussion of a NIST traceable standard;
  2. Biological controls in Clinical FCM: the use of stabilized whole blood samples and cryopreserved cells for normals and chronic lymphocytic leukemia (CLL);
  3. Third-party flow cytometry data analysis software; and
  4. Overview of FDA regulation of Clinical FCM using the 510(k) clearance process.

Back to Top Arrow



8:00-8:05 am Welcome Gerald Marti, MD, PhD
8:05-8:10 am Introduction Maria Chan, PhD
8:10-8:30 am Overview of FDA Device Regulation Kevin Maher, PhD

Session 1:  Analytical Challenges in Standardization and Validation of FCM

8:30-9:00 am Joint NIST ISAC Standardization Framework for Quantitative Flow Cytometry Lili Wang, PhD
9:00-9:30 am NIAID NIH Nature Protocol for Quality Assurance for Multicolor FCM Using a Suite of Calibration Beads Stephen P. Perfetto, MS MT (ASCP)
9:30-10:00 am Multicolor Bead Flow Cytometry Standardization Heba Degheidy, MD, PhD,
10:00-10:30 am Break  
10:30-11:00 am UK NEQAS Proficiency Testing in Acute and Chronic Leukemias David Barnett, PhD
11:00-11:30 am Background on College of American Pathologists (CAP) Proficiency Testing for Leukemia/Lymphoma Eric Hsi, MD
11:30 am-12:30 pm Lunch  

Session 2:  Transitioning from Analytical to Clinical QC in FCM

12:30-1:00 pm The Role of Biomarkers in Clinical Trials and the Fit-for-Purpose Method Validation Approach / Flow Cytometry Validation for Drug Development Instruments Virginia Litwin, PhD, Cherie Green, BS
1:00-1:30 pm LDTs in Flow Cytometry:  ICSH/ICCS Guidelines for Validation of Fluorescent Cell-based Diagnostic Testing Teri Oldaker, MLS, (ASCP), QCYM
1:30-2:00 pm Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Maryalice Stetler-Stevenson, MD, PhD
2:00-2:30 pm Break  
2:30-3:30 pm Public Comment Session Shyam Kalavar, Moderator
3:30-4:30 pm Panel Discussion:  Virginia Litwin, PhD; Teri Oldaker; Stephen Perfetto; Maryalice Stetler-Stevenson, MD, PhD Lea Carrington, Moderator
4:30-5:00 pm Wrap Up Summary and Adjourn for the Day Tremel Faison, MS, RAC, SCT (ASCP)

Session 3:  Clinical Diagnostic Flow Cytometry

8:00-8:15 am Welcome and Summary of Previous Day Tremel Faison, MS, RAC, SCT (ASCP)
8:15-8:45 am Bethesda Consensus Conference on Clinical Flow Cytometry of Hematolymphoid Malignancies Brent Wood, MD, PhD
8:45-9:15 am Euroflow: Standardization, Monoclonal Antibody Selection and Panel Configuration Tomas Kalina, MD, PhD  
9:15-9:45 am Different Approaches to Harmonisation and Standardisation - Experience from ERIC, EMN, Euroflow and ESCCA Andy C. Rawstron, PhD
9:45-10:15 am Break  
10:15-10:45 am A Model for Harmonizing Flow Cytometry in Clinical Trials – The HIPC Lyoplate Experience Phillip McCoy, PhD
10:45-11:45 am Panel Discussion:  David Barnett, PhD; Robert Becker, MD, PhD; Raul Braylan, MD; Tomas Kalina, MD, PhD; Brent Wood, MD, PhD Jennifer Dickey, Moderator
11:45 am-12:45 pm Lunch  

Session 4:  Flow Cytometry Data Analysis Software

12:45-1:15 pm Perspective on Software Pitfalls and Challenges Brent Wood, MD, PhD
1:15-2:15 pm Public Comment Session  
2:15-2:45 pm Break  
2:45-3:45 pm Panel Discussion:   Michael Borowitz, MD, PhD; Raul Braylan, MD; Maryalice Stetler-Stevenson, MD, PhD; Brent Wood, MD, PhD Nicholas Anderson, Moderator
3:45-4:30 pm Wrap-up Summary and Adjourn the Meeting Maria Chan, PhD

Back to Top Arrow

Public Comment

If you wish to make an oral presentation during any of the open comment sessions at the meeting you must indicate this at the time of registration. FDA requests that presentations focus on the areas defined in the Federal Register Notice. You should also identify which discussion topic you wish to address in your comments. In order to keep each open public comment session focused on the discussion topic at hand, each comment should address only one discussion topic. FDA will do its best to accommodate requests to speak.

In order to obtain public comment, FDA is also soliciting either electronic or written comments on the issues discussed. The deadline for submitting comments is by 5 p.m. on April 1, 2013. Regardless of attendance at the meeting, interested persons may submit either written comments regarding this document to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm.1061, Rockville, MD 20852 or electronic comments to

Back to Top Arrow

Contact Us

For questions regarding workshop content please contact:

Carol Krueger
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Ave.
Bldg. 66, rm. 5437
Silver Spring, MD 20993-0002
Phone: 301-796-3241

Back to Top Arrow

Page Last Updated: 07/10/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.